ZNRF3 and metastatic prostate carcinoma: In regard to ZNRF3, 1.8% of metastatic prostate cancer patients are reported to harbor genetic alterations, in comparison to just 0.2–0.44% of patients with the primary disease (Tables S1–S4) [64,65,66].